Distinctive Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis.

Introduction: Osteoarthritis (OA) is disabling and degenerative disease of the joints that is clinically characterized by pain and loss of function. With no disease-modifying treatment available, current therapies aim at pain management but are of limited efficacy. Cannabis products, specifically cannabinoids, are widely used to control pain and inflammation in many diseases with no scientific evidence demonstrating their efficacy in OA. Objective: We investigated the effects of non-euphorigenic cannabis extracts, CBD oil and cannabigerol oil (CBG oil), on pain and disease progression in OA mice. Methods and Results: Twelve-week-old male C57BL/6J mice received either sham or destabilization of the medial meniscus (DMM) surgery. DMM mice were treated with vehicle, CBD oil, or CBG oil. The gait of DMM mice was impaired as early as 2 weeks following surgery and continued deteriorating until week 8, which was restored by CBD oil and CBG oil treatments throughout the disease course. Mechanical allodynia developed in DMM mice, however, was not ameliorated by any of the treatments. On the other hand, both CBD oil and CBG oil ameliorated cold allodynia. In open field test, both oil treatments normalized changes in the locomotor activity of DMM mice. CBD oil and CBG oil treatments significantly reduced synovitis in DMM mice. Only CBG oil reduced cartilage degeneration, chondrocyte loss, and matrix metalloproteinase 13 expression, with a significant increase in the number of anabolic chondrocytes. Subchondral bone remodeling found in vehicle-treated DMM mice was not ameliorated by either CBD or CBG oil. Conclusions: Our results show evidence for the therapeutic efficacy of CBD oil and CBG oil, where both oils ameliorate pain and inflammation, and improve gait and locomotor activity in OA mice, representing clinical pain and function. Importantly, only CBG oil is chondroprotective, which may provide superior efficacy in future studies in OA patients.

[1]  T. Alexa-Stratulat,et al.  Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors? , 2021, Pharmaceutics.

[2]  J. Mlost,et al.  Computational Approach Reveals Pronociceptive Potential of Cannabidiol in Osteoarthritis: Role of Transient Receptor Potential Channels , 2021, Pharmaceuticals.

[3]  M. Feldmann,et al.  Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity , 2021, Molecules.

[4]  C. Page,et al.  The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. , 2021, Pulmonary pharmacology & therapeutics.

[5]  M. Zuscik,et al.  Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis , 2021, Science Translational Medicine.

[6]  K. Vrana,et al.  The Pharmacological Case for Cannabigerol , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[7]  J. Mlost,et al.  Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action , 2020, International journal of molecular sciences.

[8]  J. Mlost,et al.  Alterations in Anandamide Synthesis and Degradation during Osteoarthritis Progression in an Animal Model , 2020, International journal of molecular sciences.

[9]  M. Lamghari,et al.  Nociceptive mechanisms driving pain in a post-traumatic osteoarthritis mouse model , 2020, Scientific Reports.

[10]  N. Mantri,et al.  It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets , 2020, Molecules.

[11]  R. Elbarbary,et al.  Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model. , 2020, Journal of visualized experiments : JoVE.

[12]  B. Abramoff,et al.  Osteoarthritis: Pathology, Diagnosis, and Treatment Options. , 2020, The Medical clinics of North America.

[13]  C. Stevens,et al.  Models of Osteoarthritis: Relevance and New Insights , 2020, Calcified Tissue International.

[14]  B. Bauer,et al.  Clinicians' Guide to Cannabidiol and Hemp Oils. , 2019, Mayo Clinic proceedings.

[15]  Huilin Yang,et al.  A selective CB2 agonist protects against the inflammatory response and joint destruction in collagen-induced arthritis mice. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  Y. Bouter,et al.  Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice , 2019, Front. Behav. Neurosci..

[17]  N. Małek,et al.  Joint problems arising from lack of repair mechanisms: can cannabinoids help? , 2019, British journal of pharmacology.

[18]  O. Viswanath,et al.  An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine , 2019, Pain and Therapy.

[19]  M. Alaverdashvili,et al.  Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors , 2018, British journal of pharmacology.

[20]  E. Mazzon,et al.  In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid , 2018, International journal of molecular sciences.

[21]  J. McDougall,et al.  Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids , 2018, Current opinion in pharmacology.

[22]  J. McDougall,et al.  Osteoarthritis: the genesis of pain , 2018, Rheumatology.

[23]  Irina Vetter,et al.  Methods Used to Evaluate Pain Behaviors in Rodents , 2017, Front. Mol. Neurosci..

[24]  J. McDougall,et al.  Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis , 2017, Pain.

[25]  S. Grässel,et al.  Peripheral Nerve Fibers and Their Neurotransmitters in Osteoarthritis Pathology , 2017, International journal of molecular sciences.

[26]  G. Lubec,et al.  Individual Differences in Male Rats in a Behavioral Test Battery: A Multivariate Statistical Approach , 2017, Frontiers in behavioral neuroscience.

[27]  Ethan B. Russo.  Beyond Cannabis: Plants and the Endocannabinoid System. , 2016, Trends in pharmacological sciences.

[28]  C. L. Le Maitre,et al.  Expression of Cannabinoid Receptors in Human Osteoarthritic Cartilage: Implications for Future Therapies , 2016, Cannabis and cannabinoid research.

[29]  W. Ferrell,et al.  Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology , 2015, Annals of the rheumatic diseases.

[30]  D. Walsh,et al.  Calcitonin gene‐related peptide in the joint: contributions to pain and inflammation , 2015, British journal of clinical pharmacology.

[31]  S. Ralston,et al.  The type 2 cannabinoid receptor regulates susceptibility to osteoarthritis in mice. , 2015, Osteoarthritis and cartilage.

[32]  Q. Tong,et al.  The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. , 2015, International immunopharmacology.

[33]  C. Page,et al.  The Effect of Phytocannabinoids on Airway Hyper-Responsiveness, Airway Inflammation, and Cough , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[34]  H. Nakagawa,et al.  Changes in peptidergic fiber density in the synovium of mice with collagenase-induced acute arthritis. , 2015, Canadian journal of physiology and pharmacology.

[35]  F. Luyten,et al.  Targets, models and challenges in osteoarthritis research , 2015, Disease Models & Mechanisms.

[36]  A. Gelber,et al.  Osteoarthritis , 2020, Annals of Internal Medicine.

[37]  J. Van Oosterwijck,et al.  Evidence for central sensitization in patients with osteoarthritis pain: A systematic literature review , 2014, European journal of pain.

[38]  H. Fang,et al.  Mouse models of osteoarthritis: modelling risk factors and assessing outcomes , 2014, Nature Reviews Rheumatology.

[39]  S. Yamaguchi,et al.  Preventive effects of hyaluronan from deterioration of gait parameters in surgically induced mice osteoarthritic knee model. , 2014, Osteoarthritis and cartilage.

[40]  L. Chan,et al.  Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. , 2014, Archives of physical medicine and rehabilitation.

[41]  C. L. Le Maitre,et al.  Cannabinoid WIN-55,212-2 mesylate inhibits interleukin-1β induced matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression in human chondrocytes. , 2014, Osteoarthritis and cartilage.

[42]  Changqing Zhang,et al.  Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes , 2013, Arthritis Research & Therapy.

[43]  T. Schnitzer,et al.  Towards a mechanism-based approach to pain management in osteoarthritis , 2013, Nature Reviews Rheumatology.

[44]  H. Schaible,et al.  The innervation of synovium of human osteoarthritic joints in comparison with normal rat and sheep synovium. , 2013, Osteoarthritis and cartilage.

[45]  B. Dawson,et al.  Pain, motor and gait assessment of murine osteoarthritis in a cruciate ligament transection model. , 2013, Osteoarthritis and cartilage.

[46]  J. McDougall,et al.  A commentary on modelling osteoarthritis pain in small animals. , 2013, Osteoarthritis and cartilage.

[47]  R. Capasso,et al.  Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. , 2013, Biochemical pharmacology.

[48]  J. Schoones,et al.  Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. , 2012, Osteoarthritis and cartilage.

[49]  Richard J. Miller,et al.  CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis , 2012, Proceedings of the National Academy of Sciences.

[50]  C. Beck,et al.  Establishment of an index with increased sensitivity for assessing murine arthritis , 2011, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[51]  P. C. Karlsson,et al.  Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. , 2011, Biological & pharmaceutical bulletin.

[52]  J. Mogil,et al.  ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization. , 2010, Osteoarthritis and Cartilage.

[53]  M. Harrison,et al.  Associations between chronic disease, age and physical and mental health status. , 2009, Chronic diseases in Canada.

[54]  A. Reeve,et al.  Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis , 2008, Arthritis research & therapy.

[55]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[56]  S. Glasson,et al.  The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. , 2007, Osteoarthritis and cartilage.

[57]  A. Patapoutian,et al.  TRPM8 Is Required for Cold Sensation in Mice , 2007, Neuron.

[58]  W. Katon,et al.  The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. , 2007, General hospital psychiatry.

[59]  R. Pertwee,et al.  Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro , 2007, British journal of pharmacology.

[60]  K. Rainsford,et al.  Arthritis and cannabinoids: HU‐210 and Win‐55,212–2 prevent IL‐1 α‐induced matrix degradation in bovine articular chondrocytes in‐vitro , 2006, The Journal of pharmacy and pharmacology.

[61]  A. Zaninelli,et al.  Osteoarthritis: an overview of the disease and its treatment strategies. , 2005, Seminars in arthritis and rheumatism.